Ugur Sahin, BioNTech CEO (Jan Haas/picture-alliance/dpa/AP Images)

BioN­Tech chief Ugur Sahin gains star sta­tus in the ex­clu­sive Cov­il­lion­aire club

Rid­ding the world of Covid-19 is a lu­cra­tive en­ter­prise.

As an­a­lysts divvy up the multi­bil­lion-dol­lar re­wards in line for the lead­ers in the race to roll out the first pan­dem­ic vac­cines, no one is for­get­ting to track just how much the top com­pa­ny founders have on the line now as stock prices gy­rate ever high­er.

Bloomberg, which tracks these num­bers with mis­sion­ary zeal, puts Sahin’s net worth to­day at $5.1 bil­lion fol­low­ing the most re­cent rise of BioN­Tech’s $BN­TX share price. The biotech’s part­ner, Pfiz­er, is ag­gres­sive­ly push­ing ahead with plans to get the first ap­proved vac­cine in play, and Bern­stein be­lieves that will put the two col­lab­o­ra­tors in line for the largest mar­ket share for next year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.